<DOC>
	<DOCNO>NCT00349427</DOCNO>
	<brief_summary>This study design demonstrate addition rosiglitazone ( 4mg ) insulin Type 2 diabetes mellitus subject achieve glycemic goal insulin injection alone efficacious term improve glycemic control .</brief_summary>
	<brief_title>A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion : Patients type 2 Diabetes mellitus minimum dose 30 units/day insulin monotherapy continuously least 8 week If Patients take another oral antidiabetic agent may stop oral agent adjust insulin dose properly 8 week prior screen ask doctor considers him/her suitable study respect , HbA1c level &gt; 7.5 % . Exclusion : Fasting plasma glucose &gt; 13 mmol/L screen Ongoing edema history peripheral edema require pharmacological treatment within 12 month Drug abuse Women pregnant lactating Use rosiglitazone like drug 3 month Use one oral antidiabetic agent 2 month Uncontrolled hypertension Chronic heart failure Anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Insulin</keyword>
	<keyword>BRL49653 /rosiglitazone</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>